United Kingdom (UK)
Recombinant monoclonal antibody to CTLA-4. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 5E3.
UniProt Accession Number of Target Protein: P16410
Alternative Name(s) of Target: Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; CD152
Immunogen: The original antibody was generated by immunizing BALB/c mice with CTLA-4 protein.
Specificity: The antibody is specific for CTLA-4. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses.
Application Notes: The specificity of the antibody was confirmed by ELISA analysis. The kinetic parameters of human CTLA-4 protein binding to the antibody were measured and they resulted to be at the sub-nm level. The antitumor activity of the humanized antibody was demonstrated in vivo in animal models. It was proved that the antibody inhibited the tumor in a dose-dependent manner. Mouse PD-1 antibody was combined with the antibody and used to evaluate the toxicity to mice; these experiments compared with the use of Ipilimumab in combination with PD-1 antibody. Results showed that after 5E3 antibody was used in combination with PD-1 antibody, the immunity to the body and the toxicity of heart, liver and lung are significantly lower than the toxicity of Ipilimumab in combination with PD-1 antibody (CN110343180).
Antibody first published in: PMID: